Indian Entrepreneur@indianentrepreneurAnthropic, the company behind Claude, is pushing its AI further into drug discovery. It has partnered with six firms, including Bristol Myers Squibb, to speed up several stages of making medicines.
Generate Biomedicines is adapting CAR T-cell therapy, usually used on blood cancers, for solid tumours, and a redesigned genetic section it drafted with Claude Code helped immune cells make roughly 10 times more receptors in lab tests.
Much of this work is still preclinical, though one muscular dystrophy candidate could enter human trials as early as late 2028 if early results hold up.
